Becton, Dickinson and Company (BDX)
After hours:
| Previous close | 232.21 |
| Open | 232.61 |
| Bid | 0.00 x 1100 |
| Ask | 0.00 x 1100 |
| Day's range | 230.47 - 233.25 |
| 52-week range | 229.40 - 287.32 |
| Volume | |
| Avg. volume | 1,365,916 |
| Market cap | 67.358B |
| Beta (5Y monthly) | 0.46 |
| PE ratio (TTM) | 53.47 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 3.80 (1.63%) |
| Ex-dividend date | 07 Mar 2024 |
| 1y target est | N/A |
- PR Newswire
BD Named a Best Employer for Excellence in Employee Well-Being
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will receive the Business Group on Health "Best Employers: Excellence in Health & Well-being Award" for its commitment to advancing employee well-being through comprehensive and innovative benefits and initiatives.
- PR Newswire
BD Increases Access to Cutting-Edge Image-Enabled, Spectral Cell Sorters
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the global commercial release of new cell sorters that will enable more researchers in a broader range of fields, including cell biology, cancer research and immunology, to reveal insights that were previously invisible in traditional flow cytometry experiments.
- PR Newswire
BD to Announce Financial Results for its Second Quarter of Fiscal 2024
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will report financial results for its second quarter of fiscal year 2024 on Thursday, May 2, 2024. A news release will be issued at approximately 6:30 a.m. Eastern Time (ET) and will be available at www.bd.com/investors, along with related presentation materials. The news release and presentation materials will include summary financial information for the company's second quarter
